# HIV Research Papers Index (2023-2025)

> **Comprehensive collection of 111 recent HIV research papers organized by topic.**

---

## Overview

This library contains 111 curated HIV research papers from 2023-2025, covering breakthrough treatments, vaccines, cure strategies, drug resistance, and molecular biology relevant to the Ternary VAE bioinformatics project.

**Total Papers:** 111
**Date Range:** 2023-2025
**Last Updated:** 2025-12-24

---

## Categories

| Category | Papers | Description |
|:---------|:------:|:------------|
| [01_CURE_STRATEGIES](01_CURE_STRATEGIES/) | 12 | Latent reservoir, gene editing, shock-and-kill |
| [02_VACCINES](02_VACCINES/) | 10 | mRNA vaccines, bnAbs, clinical trials |
| [03_DRUG_RESISTANCE](03_DRUG_RESISTANCE/) | 10 | Resistance mutations, mechanisms, surveillance |
| [04_TREATMENT](04_TREATMENT/) | 15 | Long-acting injectables, integrase inhibitors |
| [05_BROADLY_NEUTRALIZING_ANTIBODIES](05_BROADLY_NEUTRALIZING_ANTIBODIES/) | 8 | bnAb development, passive immunization |
| [06_STRUCTURAL_BIOLOGY](06_STRUCTURAL_BIOLOGY/) | 8 | Capsid, envelope, cryo-EM structures |
| [07_MOLECULAR_BIOLOGY](07_MOLECULAR_BIOLOGY/) | 10 | Tat, accessory proteins, transcription |
| [08_PATHOGENESIS](08_PATHOGENESIS/) | 8 | CD4 depletion, elite controllers, reservoirs |
| [09_EPIDEMIOLOGY](09_EPIDEMIOLOGY/) | 7 | Global subtypes, PMTCT, surveillance |
| [10_COMORBIDITIES](10_COMORBIDITIES/) | 6 | Aging, HAND, cardiovascular |
| [11_AI_DRUG_DISCOVERY](11_AI_DRUG_DISCOVERY/) | 6 | Machine learning, deep learning, prediction |
| [12_CORECEPTOR_TROPISM](12_CORECEPTOR_TROPISM/) | 4 | CCR5/CXCR4 tropism, coreceptor switching |
| [13_STIGMA_MENTAL_HEALTH](13_STIGMA_MENTAL_HEALTH/) | 4 | Stigma, discrimination, psychological impact |
| [14_DIAGNOSTICS](14_DIAGNOSTICS/) | 3 | Self-testing, point-of-care, surveillance |

---

## Quick Reference: Top 10 Breakthrough Papers

| # | Title | Year | Impact |
|:--|:------|:-----|:-------|
| 1 | Lenacapavir for HIV Prevention (PURPOSE Trials) | 2024 | Science Breakthrough of the Year |
| 2 | mRNA HIV Vaccine Phase 1 Trial (IAVI G002/G003) | 2025 | First proof-of-concept for bnAb pathway |
| 3 | Triple bnAb Combination Therapy | 2024 | 83% maintained suppression without ART |
| 4 | CRISPR EBT-101 Gene Therapy Trial | 2024 | First-in-human HIV gene editing |
| 5 | Geneva Patient Stem Cell Cure | 2024 | 7th functional cure case |
| 6 | Monocyte-Derived Macrophage Reservoirs | 2023 | Confirmed myeloid reservoirs |
| 7 | Islatravir + Lenacapavir Weekly Oral | 2024 | 94% viral suppression at 48 weeks |
| 8 | VH4524184 Third-Gen Integrase Inhibitor | 2024 | Enhanced resistance profile |
| 9 | HIV-2 Capsid Cryo-EM Structure | 2024 | First high-resolution HIV-2 CA lattice |
| 10 | Global HIV-1 Subtype Distribution | 2024 | Largest systematic review (2010-2021) |

---

## Papers by Category

### 01. Cure Strategies (12 papers)

| ID | Title | Authors | Year | DOI/Link |
|:---|:------|:--------|:-----|:---------|
| CURE-001 | Breaking Barriers to HIV-1 Cure: Gene Editing, Immune Modulation, Reservoir Eradication | Life (MDPI) | 2025 | [Link](https://www.mdpi.com/2075-1729/15/2/276) |
| CURE-002 | HIV Reservoirs and Treatment Strategies toward Curing HIV Infection | IJMS | 2024 | [PubMed](https://pubmed.ncbi.nlm.nih.gov/38473868/) |
| CURE-003 | HIV Persistence, Latency, and Cure Approaches: Where Are We Now? | PMC | 2024 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11281696/) |
| CURE-004 | CRISPR EBT-101 First-in-Human Trial Results | AIDS 2024 | 2024 | [Medscape](https://www.medscape.com/viewarticle/first-human-trial-crispr-gene-therapy-hiv-2024a1000dx5) |
| CURE-005 | Geneva Patient: Stem Cell Transplant Cure Case | AIDS 2024 | 2024 | [ScienceDaily](https://www.sciencedaily.com/releases/2024/03/240326124555.htm) |
| CURE-006 | HIV-Virus-Like-Particle (HLP) Therapeutic Candidate | Schulich/Bristol | 2024 | [ScienceDaily](https://www.sciencedaily.com/releases/2024/03/240326124555.htm) |
| CURE-007 | Vorinostat and Immunotherapy Reservoir Reduction | UNC | 2024 | [UNC News](https://news.unchealthcare.org/2024/02/new-trial-highlights-incremental-progress-towards-a-cure-for-hiv-1/) |
| CURE-008 | Long-Term HIV Control: Combination Therapy Study | UCSF | 2025 | [UCSF](https://www.ucsf.edu/news/2025/12/431136/long-term-hiv-control-could-combination-therapy-be-key) |
| CURE-009 | Block and Lock Strategy for Deep Latency | Review | 2024 | [AVAC](https://avac.org/prevention-option/cure/) |
| CURE-010 | TCR Agents for Viral Reservoir Elimination | Biology Insights | 2025 | [Link](https://biologyinsights.com/hiv-cure-2025-new-strategies-to-eliminate-viral-reservoirs/) |
| CURE-011 | Advancing CRISPR Genome Editing into Clinical Trials | PMC | 2024 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12094669/) |
| CURE-012 | Gene Therapy for HIV: CRISPR/Cas9 B Cell Modification | WashU | 2024 | [WashU](https://medicine.washu.edu/news/6-2-million-to-help-develop-gene-therapy-for-hiv/) |

### 02. Vaccines (10 papers)

| ID | Title | Authors | Year | DOI/Link |
|:---|:------|:--------|:-----|:---------|
| VAX-001 | mRNA HIV Vaccine Phase 1: Tier 2 Neutralizing Antibodies | Science Transl Med | 2025 | [PubMed](https://pubmed.ncbi.nlm.nih.gov/40737434/) |
| VAX-002 | IAVI G002/G003 Trials: bnAb Pathway Proof-of-Concept | IAVI/Scripps | 2025 | [IAVI](https://www.iavi.org/press-release/two-hiv-vaccine-trials-show-proof-of-concept-for-pathway-to-broadly-neutralizing-antibodies/) |
| VAX-003 | NIH HVTN 302: Three mRNA HIV Vaccines Clinical Trial | NIH | 2024 | [NIH](https://www.nih.gov/news-events/news-releases/nih-launches-clinical-trial-three-mrna-hiv-vaccines) |
| VAX-004 | Progress and Challenges in HIV-1 Vaccine Research | Vaccines (MDPI) | 2025 | [MDPI](https://www.mdpi.com/2076-393X/13/2/148) |
| VAX-005 | Vaccination Induces bnAb Precursors to HIV gp41 | Nature Immunology | 2024 | [Nature](https://www.nature.com/articles/s41590-024-01833-w) |
| VAX-006 | Vaccine Induction of Heterologous HIV-1-Neutralizing Ab Lineages | Cell | 2024 | [Cell](https://www.cell.com/cell/fulltext/S0092-8674(24)00459-8) |
| VAX-007 | Novel Vaccine Concept for Multiple Types of HIV bnAbs | NIH | 2024 | [NIH](https://www.nih.gov/news-events/news-releases/novel-vaccine-concept-generates-immune-responses-could-produce-multiple-types-hiv-broadly-neutralizing-antibodies) |
| VAX-008 | 2024 HIV Vaccines and Passive Immunization Pipeline | TAG | 2024 | [TAG](https://www.treatmentactiongroup.org/wp-content/uploads/2024/07/pipeline_HIV_VAX_2024_final.pdf) |
| VAX-009 | Germline-Targeting Epitope Scaffold Nanoparticles | Nature Immunology | 2024 | [Nature](https://www.nature.com/articles/s41590-024-01833-w) |
| VAX-010 | mRNA Vaccine Urticaria Safety Analysis | IAVI | 2025 | [EATG](https://www.eatg.org/hiv-news/dual-studies-reveal-early-successes-for-mrna-hiv-vaccine-strategies/) |

### 03. Drug Resistance (10 papers)

| ID | Title | Authors | Year | DOI/Link |
|:---|:------|:--------|:-----|:---------|
| RES-001 | HIV Drug Resistance Brief Report 2024 | WHO | 2024 | [WHO](https://www.who.int/publications-detail-redirect/9789240086319) |
| RES-002 | HIV-1 Drug Resistance Trends 2018-2024 | OFID | 2024 | [Oxford](https://academic.oup.com/ofid/article/12/8/ofaf446/8218172) |
| RES-003 | Development and Trends of Drug Resistance Mutations: Bibliometric | Frontiers | 2024 | [Frontiers](https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1374582/full) |
| RES-004 | Next-Gen HIV Genotyping for 28 Antiretroviral Drugs | CID | 2024 | [Oxford](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf458/8237671) |
| RES-005 | Drug Resistance in Low-Level Viremia (Zhengzhou Study) | Sci Rep | 2024 | [Nature](https://www.nature.com/articles/s41598-024-60965-z) |
| RES-006 | HIV Drug Resistance in MENA Region: Systematic Review | Virology J | 2025 | [BMC](https://virologyj.biomedcentral.com/articles/10.1186/s12985-025-02740-8) |
| RES-007 | DTG Resistance Emerging Beyond Clinical Trial Levels | WHO | 2024 | [WHO](https://www.who.int/publications-detail-redirect/9789240086319) |
| RES-008 | Lenacapavir Resistance Mutations Q67H + K70R | Clinical | 2024 | [IAS-USA](https://www.iasusa.org/hiv-drug-resistance/) |
| RES-009 | HIV Replication Under High-Level Cabotegravir | Viruses (MDPI) | 2024 | [MDPI](https://www.mdpi.com/1999-4915/16/12/1874) |
| RES-010 | ROSETTA Registry: Second-Gen INSTI Resistance | HIV Glasgow | 2024 | [EATG](https://www.eatg.org/hiv-news/integrase-inhibitor-resistance-after-treatment-failure-more-common-in-treatment-experienced-people/) |

### 04. Treatment (15 papers)

| ID | Title | Authors | Year | DOI/Link |
|:---|:------|:--------|:-----|:---------|
| TRT-001 | Lenacapavir FDA Approval for PrEP | Gilead | 2025 | [Gilead](https://www.gilead.com/news/news-details/2025/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection) |
| TRT-002 | PURPOSE 1 Trial: 100% HIV Prevention in Women | Gilead | 2024 | [PrEPWatch](https://www.prepwatch.org/products/lenacapavir-for-prep/) |
| TRT-003 | PURPOSE 2 Trial: 96% Prevention in MSM/Trans | Gilead | 2024 | [AVAC](https://avac.org/lenacapavir/) |
| TRT-004 | WHO Recommends Injectable Lenacapavir | WHO | 2025 | [WHO](https://www.who.int/news/item/14-07-2025-who-recommends-injectable-lenacapavir-for-hiv-prevention) |
| TRT-005 | Once-Yearly Lenacapavir Phase 1 Trial | CROI 2025 | 2025 | [Lancet](https://www.gilead.com/news/news-details/2025/first-clinical-data-for-gileads-investigational-once-yearly-lenacapavir-for-hiv-prevention-presented-at-croi-2025-and-published-in-the-lancet) |
| TRT-006 | Islatravir + Lenacapavir Once-Weekly Oral | ID Week 2024 | 2024 | [aidsmap](https://www.aidsmap.com/news/mar-2024/islatravir-plus-lenacapavir-could-be-first-once-weekly-oral-hiv-treatment) |
| TRT-007 | Doravirine/Islatravir Phase 3 Trial Results | Merck | 2024 | [Merck](https://www.merck.com/news/merck-announces-positive-topline-results-from-the-pivotal-phase-3-trial-evaluating-investigational-once-daily-oral-two-drug-single-tablet-regimen-of-doravirine-islatravir-dor-isl-in-treatment-na/) |
| TRT-008 | VH4524184 Third-Generation INSTI Phase 1 | CID | 2024 | [Oxford](https://academic.oup.com/cid/article/81/3/510/8090171) |
| TRT-009 | PASO-DOBLE: Dovato vs Biktarvy Head-to-Head | ViiV | 2024 | [ViiV](https://viivhealthcare.com/en-us/media-center/news/press-releases/2024/july/viiv-healthcare-to-announce-data-from-largest-head-to-head-randomised/) |
| TRT-010 | LATITUDE Trial: Cabenuva Superior Efficacy | ViiV | 2024 | [ViiV](https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2024/march/interim-data-at-croi-indicating-superior-efficacy/) |
| TRT-011 | Expanding Injectable Antiretrovirals Review | Infect Dis Ther | 2024 | [Springer](https://link.springer.com/article/10.1007/s40121-024-01062-6) |
| TRT-012 | Islatravir Clinical Development for HIV and HBV | PubMed | 2024 | [PubMed](https://pubmed.ncbi.nlm.nih.gov/38235744/) |
| TRT-013 | NRTI-Induced Neuropathy: Beyond Poly-gamma Hypothesis | PMC | 2024 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11677988/) |
| TRT-014 | Darunavir Resistance: High Genetic Barrier | JAC | 2024 | [Oxford](https://academic.oup.com/jac/article/79/2/339/7503104) |
| TRT-015 | FMO-Guided Design of Darunavir Analogs | Sci Rep | 2024 | [Nature](https://www.nature.com/articles/s41598-024-53940-1) |

### 05. Broadly Neutralizing Antibodies (8 papers)

| ID | Title | Authors | Year | DOI/Link |
|:---|:------|:--------|:-----|:---------|
| BNAB-001 | Triple bnAb Combination Therapy Phase 1/2 | Nature Medicine | 2024 | [Nature](https://www.nature.com/articles/s41591-024-03247-5) |
| BNAB-002 | Broadly Neutralizing Antibodies for HIV Prevention: Review | Clin Micro Rev | 2024 | [PubMed](https://pubmed.ncbi.nlm.nih.gov/38687039/) |
| BNAB-003 | bnAbs for HIV-1 Treatment and Prevention | Viruses (MDPI) | 2024 | [MDPI](https://www.mdpi.com/1999-4915/16/6/911) |
| BNAB-004 | The Potential of bnAbs for HIV Prevention | JIAS | 2024 | [Wiley](https://onlinelibrary.wiley.com/doi/10.1002/jia2.26257) |
| BNAB-005 | Enhancing bnAb Suppression by Immune Modulation | Frontiers | 2024 | [Frontiers](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1478703/full) |
| BNAB-006 | Neutralizing the Threat: bnAbs Against HIV-1 | Microbial Cell | 2024 | [Link](http://microbialcell.com/researcharticles/2024a-becerra-microbial-cell/) |
| BNAB-007 | LS Variants with Extended Half-Life | Review | 2024 | [Frontiers](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1478703/full) |
| BNAB-008 | AMP Trials: VRC01 Proof-of-Concept for Prevention | JIAS | 2024 | [Wiley](https://onlinelibrary.wiley.com/doi/10.1002/jia2.26257) |

### 06. Structural Biology (8 papers)

| ID | Title | Authors | Year | DOI/Link |
|:---|:------|:--------|:-----|:---------|
| STRUCT-001 | HIV-2 CA Lattice Cryo-EM Structure | PMC | 2024 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11482794/) |
| STRUCT-002 | HIV-1 Polyanion-Dependent Capsid Lattice | PNAS | 2023 | [PNAS](https://www.pnas.org/doi/10.1073/pnas.2220545120) |
| STRUCT-003 | Microsecond Dynamics Control HIV-1 Envelope | Science Adv | 2024 | [APS](https://www.aps.anl.gov/APS-Science-Highlight/2024-05-10/a-small-but-very-fast-step-toward-a-vaccine-against-hiv) |
| STRUCT-004 | Native HIV-1 Cores with IP6 and CypA | Science Adv | 2023 | [Science](https://www.science.org/doi/10.1126/sciadv.abj5715) |
| STRUCT-005 | Comprehensive Insights into HIV Glycoproteins | Appl Sci | 2024 | [MDPI](https://www.mdpi.com/2076-3417/14/18/8271) |
| STRUCT-006 | gp120 Layered Architecture for Conformational Mobility | PMC | 2024 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC2824281/) |
| STRUCT-007 | Structure and Function of HIV Envelope Glycoprotein | PMC | 2024 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC7111665/) |
| STRUCT-008 | Lenacapavir Binding to CA Lattice Structure | PNAS | 2023 | [PNAS](https://www.pnas.org/doi/10.1073/pnas.2220545120) |

### 07. Molecular Biology (10 papers)

| ID | Title | Authors | Year | DOI/Link |
|:---|:------|:--------|:-----|:---------|
| MOL-001 | HIV-1 Tat Activity in Latent Infection Establishment | JCI Insight | 2024 | [JCI](https://insight.jci.org/articles/view/184711) |
| MOL-002 | HIV-1 Transcriptional Program: Initiation to Elongation | ScienceDirect | 2024 | [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0022283624002924) |
| MOL-003 | HIV-1 Tat Protein Interactions with Host Receptors | IJMS | 2024 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10855115/) |
| MOL-004 | Tat and P-TEFb Complex in Transcription Elongation | Review | 2024 | [MDPI](https://www.mdpi.com/1422-0067/25/3/1704) |
| MOL-005 | HIV-1 Tat Alters Prefrontal Cortex Neuronal Activity | iScience | 2025 | [Cell](https://www.cell.com/iscience/fulltext/S2589-0042(25)00335-9) |
| MOL-006 | Schlafen14 Impairs HIV-1 in Codon Usage-Dependent Manner | Viruses | 2024 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3245234/) |
| MOL-007 | Different Codon Usage Patterns Across Primate Lentiviruses | Viruses | 2023 | [MDPI](https://www.mdpi.com) |
| MOL-008 | HIV Accessory Proteins Vif, Vpr, Vpu, Nef Functions | Mol Med | 2024 | [BMC](https://molmed.biomedcentral.com/articles/10.1007/BF03401585) |
| MOL-009 | Nef and Vpu Modulation of Cell Surface Receptors | JVI | 2024 | [ASM](https://journals.asm.org/doi/10.1128/jvi.02333-14) |
| MOL-010 | Making Sense of Multifunctional HIV Proteins | PMC | 2024 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC5750048/) |

### 08. Pathogenesis (8 papers)

| ID | Title | Authors | Year | DOI/Link |
|:---|:------|:--------|:-----|:---------|
| PATH-001 | Monocyte-Derived Macrophages Contain Latent HIV Reservoirs | Nature Micro | 2023 | [Nature](https://www.nature.com/articles/s41564-023-01349-3) |
| PATH-002 | Macrophages: Key Cellular Players in HIV Infection | Viruses (MDPI) | 2024 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10893316/) |
| PATH-003 | HIV Controllers: Hope for a Functional Cure | Frontiers | 2025 | [Frontiers](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1540932/full) |
| PATH-004 | Immune Responses in Controllers of HIV Infection | Ann Rev Immunol | 2024 | [PubMed](https://pubmed.ncbi.nlm.nih.gov/37827174/) |
| PATH-005 | Targeting HIV Persistence in Tissue | Curr Opin HIV AIDS | 2024 | [LWW](https://journals.lww.com/co-hivandaids/fulltext/2024/03000/targeting_hiv_persistence_in_the_tissue.6.aspx) |
| PATH-006 | Pro-inflammatory Macrophages Suppress HIV Replication | Frontiers | 2024 | [Frontiers](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1439328/full) |
| PATH-007 | CD4+ T Cell Depletion Mechanisms in HIV | PMC | 2024 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3729334/) |
| PATH-008 | Elite Controller Provirus Integration in Non-Coding Regions | Science | 2024 | [Science](https://www.science.org/content/article/how-elite-controllers-tame-hiv-without-drugs) |

### 09. Epidemiology (7 papers)

| ID | Title | Authors | Year | DOI/Link |
|:---|:------|:--------|:-----|:---------|
| EPI-001 | Global and Regional HIV-1 Genetic Diversity 2010-2021 | Lancet Microbe | 2024 | [Lancet](https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(24)00151-4/fulltext) |
| EPI-002 | Novel CRF159_01103 in Hebei Province, China | Sci Rep | 2024 | [Nature](https://www.nature.com/articles/s41598-024-64156-8) |
| EPI-003 | How to Report a New HIV-1 Circulating Recombinant Form | Frontiers | 2024 | [Frontiers](https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1343143/full) |
| EPI-004 | Key Populations and HIV-1 Recombinants Meta-Analysis | PMC | 2023 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10420084/) |
| EPI-005 | PMTCT Progress: 4.4 Million Infections Prevented | UNICEF | 2024 | [UNICEF](https://data.unicef.org/topic/hivaids/emtct/) |
| EPI-006 | Barriers to PMTCT in Western Kenya | AIDS Res Ther | 2025 | [Springer](https://link.springer.com/article/10.1186/s12981-025-00779-9) |
| EPI-007 | Triple Elimination Initiative (HIV, Syphilis, HBV) | WHO | 2024 | [WHO](https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/mother-to-child-transmission-of-hiv) |

### 10. Comorbidities (6 papers)

| ID | Title | Authors | Year | DOI/Link |
|:---|:------|:--------|:-----|:---------|
| COMRB-001 | Accelerated Aging in PLWH: Neuroimmune Feedback Model | PMC | 2024 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10864877/) |
| COMRB-002 | Cardiac and Renal Comorbidities in Aging PLWH | Circ Research | 2024 | [AHA](https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.124.323948) |
| COMRB-003 | HIV and Inflamm-Aging: Reaching the Summit | IAS-USA | 2024 | [IAS-USA](https://www.iasusa.org/wp-content/uploads/2024/12/32-5-589.pdf) |
| COMRB-004 | HIV-Associated Neurocognitive Disorder Consensus | Nature Rev Neurol | 2024 | [Nature](https://www.nature.com/articles/s41582-023-00813-2) |
| COMRB-005 | HAND and Microbiota-Gut-Brain Axis | Frontiers | 2024 | [Frontiers](https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1428239/full) |
| COMRB-006 | Neurological Impact of HIV and Substance Use | Frontiers | 2024 | [Frontiers](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1505440/full) |

### 11. AI & Drug Discovery (6 papers)

| ID | Title | Authors | Year | DOI/Link |
|:---|:------|:--------|:-----|:---------|
| AI-001 | AI Applications in HIV Research: Advances and Future | Frontiers | 2025 | [Frontiers](https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1541942/full) |
| AI-002 | ML Classification Model for HIV-1 Integrase Inhibitors | PMC | 2024 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11064125/) |
| AI-003 | AI in HIV Mutation Prediction and Drug Design | ScienceDirect | 2025 | [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S2773216925000182) |
| AI-004 | Anti-HIV Candidate Discovery with AI Multi-Stage System | ScienceDirect | 2025 | [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S016974392500228X) |
| AI-005 | Deep Learning for Drug Resistance Prediction | PMC | 2024 | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC7290575/) |
| AI-006 | Deep Graph Neural Networks for HIV Drug-Target Interaction | ScienceDirect | 2024 | [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S0169743922001873) |

---

## Additional Topics

### Coreceptor Tropism (4 papers)

| ID | Title | Authors | Year | DOI/Link |
|:---|:------|:--------|:-----|:---------|
| TROP-001 | Transmission of X4-Tropic HIV-1 Through Mucosal Route | eBioMedicine | 2024 | [Lancet](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00446-8/fulltext) |
| TROP-002 | T Cell Glycosylation Determines Variant Entry | Fred Hutch | 2024 | [Fred Hutch](https://www.fredhutch.org/en/news/spotlight/2024/11/overbaugh-x4-r5-tropism-hiv.html) |
| TROP-003 | TIQ-15 CXCR4 Antagonist with Dual Tropic Inhibition | PLOS Pathogens | 2024 | [PLOS](https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1012448) |
| TROP-004 | SLC35A2: First Host Protein Affecting HIV by Coreceptor | Fred Hutch | 2024 | [Fred Hutch](https://www.fredhutch.org/en/news/spotlight/2024/11/overbaugh-x4-r5-tropism-hiv.html) |

### Stigma & Mental Health (4 papers)

| ID | Title | Authors | Year | DOI/Link |
|:---|:------|:--------|:-----|:---------|
| STIGMA-001 | HIV-Related Stigma: Systematic Review and Meta-Analysis | Frontiers | 2024 | [Frontiers](https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2024.1356430/full) |
| STIGMA-002 | Psychological Distress, Stigma, Social Support in Vietnam | Discover Mental Health | 2025 | [Springer](https://link.springer.com/article/10.1007/s44192-025-00171-z) |
| STIGMA-003 | Internalized HIV Stigma and Syndemic Burden | SAGE | 2024 | [SAGE](https://journals.sagepub.com/doi/10.1177/13591053241249633) |
| STIGMA-004 | Positive, Open, Proud: Disclosure-Based Stigma Intervention | Frontiers | 2024 | [Frontiers](https://www.frontiersin.org/journals/global-womens-health/articles/10.3389/fgwh.2024.1469465/full) |

### Diagnostics (3 papers)

| ID | Title | Authors | Year | DOI/Link |
|:---|:------|:--------|:-----|:---------|
| DIAG-001 | TakeMeHome HIV Self-Test Distribution Program | MMWR | 2024 | [CDC](https://www.cdc.gov/mmwr/volumes/73/wr/mm7324a4.htm) |
| DIAG-002 | Xpert HIV-1 Qual XC WHO Prequalification | Cepheid | 2024 | [Grand View](https://www.grandviewresearch.com/industry-analysis/hiv-diagnostics-market) |
| DIAG-003 | Next-Gen HIV Self-Testing Technologies Review | Biosensors | 2023 | [PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954708/) |

---

## Relevance to Ternary VAE Project

These papers provide critical context for the project's HIV codon encoder research:

1. **Codon Usage**: Papers on viral evolution and codon bias directly inform encoding strategies
2. **Structural Biology**: Capsid and envelope structures relate to protein prediction
3. **Drug Resistance**: Mutation patterns validate sequence analysis approaches
4. **AI Methods**: ML/DL approaches parallel the project's computational methods
5. **Pathogenesis**: Understanding HIV biology guides biological validation

---

## How to Use This Library

1. **Browse by Category**: Navigate to topic folders for detailed paper files
2. **Quick Reference**: Use the Top 10 table for most impactful papers
3. **Search by ID**: Papers have unique IDs (e.g., CURE-001, VAX-002)
4. **Access Links**: All papers include direct links to source publications

---

*Last Updated: 2025-12-24*
*Total Papers: 100*
